It is IRF's overall assessment that Acarizax may be considered a relevant add-on therapy in house dust mite allergic rhinitis and allergic asthma in adults when symptomatic treatment is not adequate. Immunotherapy is a long-term treatment form, requiring high patient motivation, and after treatment it is likely that symptomatic treatment will still be needed. There are no comparative studies against subcutaneous immunotherapy, but indirect statistical analyses suggest that the efficacy is comparable (1). Acarizax has the advantage that it is an at-home treatment, except for the first dose, which is given under the supervision of a doctor. The adverse reactions are mainly transient and show in the form of mild allergic reactions up until the first three months of treatment.
Acarizax must be taken daily for three years, and the price of treatment totals DKK 31,749.
1. Durham SR, Penagos M. Sublingual or subcutaneous immunotherapy for allergic rhinitis? The Journal of allergy and clinical immunology. 2016;137(2):339-49.e10